Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
/in Dendritic Cells, International Publications, Pancreatic CancerNeoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
/in Dendritic Cells, NSCLCAdjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaA new strategy for enhancing antitumor immune response using dendritic cells loaded with chemo-resistant cancer stem-like cells in experimental mice model
/in Dendritic Cells, International PublicationsOncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease VirusDendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
/in Acute Leukemia, Dendritic Cells, International PublicationsA double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy
/in Dendritic Cells, International Publications, Pancreatic CancerGene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
/in Dendritic Cells, HIV/AIDS, International PublicationsA Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer